News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Plandai Biotechnology, Inc. (PLPL.OB) Announces Phytofare™ Catechin Complex Can Be Used as a Dietary Supplement Without Prior FDA Notification Or Approval


6/19/2014 11:55:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, WA--(Marketwired - June 18, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has received a legal opinion from the noted law firm of Hyman, Phelps & McNamara, P.C., the largest dedicated food and drug legal firm in the country, in which it was determined that Plandaí will not be required to apply to the US Food and Drug Administration for approval to market and sell its Phytofare™ Catechin Complex as a dietary supplement. This opinion paves the way for Plandaí to immediately commence sales efforts in the United States.

The Federal Food, Drug and Cosmetic Act requires that the US FDA be notified of the use of any New Dietary Ingredient (NDI) and that the use of such ingredient be approved prior to the commencement of sales and marketing unless the NDI meets certain criteria for exemption. Phytofare™ Catechin Complex, as an NDI, qualifies for exemption since it has been present in the food supply without being chemically altered. The Dietary Supplement Health and Education Act of 1994 makes it clear that a number of "physical modifications," such as those undertaken in Plandaí's extraction and processing, do not constitute "chemical alteration."

Vice President of Sales Callum Baylis-Duffield commented, "As we gear up to commence marketing Phytofare™ in the coming quarter, qualifying for this exemption is a huge milestone. Had we been forced to apply to the FDA, the cost in terms of time, opportunity and hard dollars spent would have been tremendous. Having a firm with the reputation and standing of Hyman, Phelps & McNamara issue us this opinion gives us ideal positioning within the marketplace and enables our distributors to immediately commence marketing the product in the US and abroad."

Plandaí's first product to market will be Phytofare™ Catechin Complex, which includes the entire Catechin profile derived from live green tea that is grown and processed on the Company's 30,000 sq. ft. factory located on its Senteeko estate in South Africa. The company's Phytofare™ Citrus Complex, based on citrus bioflavonoids and limonoids, will start undergoing clinical testing later this year in anticipation of a 2015 release.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.


Contact:
Andrew Beyer
Phone: 619-202-7456
Email: investor@Plandaíbiotech.com



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES